While the broader Australian share market enjoyed a robust session, with the S&P/ASX 200 Index (ASX: XJO) climbing a solid 1.66%, not all companies managed to ride the wave of positive sentiment. Two prominent ASX 200 constituents, Computershare Ltd (ASX: CPU) and ResMed Inc (ASX: RMD), experienced significant price declines of 3.3% and 4.7% respectively. This dip, however, might present a compelling entry point for astute investors looking to acquire these stocks at a more attractive valuation. Let’s delve into what industry experts are saying about these recent movements and their future prospects.
Computershare Ltd (ASX: CPU): A Closer Look at the Numbers
Computershare, a global leader in financial administration services encompassing corporate trusts, stock transfers, and employee share plans, saw its share price falter by 3.3% following the release of its first-half FY26 results. Despite the market’s reaction, the company’s financial performance paints a generally positive picture:
- Revenue Growth: Management revenue saw a healthy increase of 3.9% when compared to the first half of FY25.
- Earnings Per Share (EPS): Management EPS also grew by 3.9%, reaching 72.2 US cents.
- Return on Invested Capital (ROIC): The company’s ROIC impressively exceeded 36%.
- Margin Income: While margin income stood at $372.9 million, it did experience a slight decrease of 5.4%.
- Dividend Payout: The interim dividend was lifted by 22% year-on-year to 55 Australian cents per share, with 30% franking.
These figures, coupled with the company’s robust balance sheet strength and an upgrade to its FY26 guidance, would typically be interpreted as strong indicators. However, it appears investors were anticipating even more significant growth.
Following yesterday’s sell-off, Computershare’s share price now hovers near its 52-week low, trading at $31.29 per share. This represents a notable decline of approximately 25% from its value this time last year. This current valuation suggests that the ASX 200 stock may now be undervalued.
Analysts at Citi, for instance, initiated a ‘buy’ rating on this industrial stalwart back in January, setting a price target of $39.60. Based on yesterday’s closing price, this target implies an upside potential of around 26.5%.
ResMed Inc (ASX: RMD): Navigating a Dip in Share Price
ResMed, a key player in the medical device sector, also experienced a challenging trading day, with its shares declining by 4.7%. The company specialises in the development, manufacturing, and distribution of innovative medical devices and cloud-based software solutions designed to diagnose, treat, and manage a wide spectrum of respiratory disorders. This includes conditions such as sleep apnea, chronic obstructive pulmonary disease (COPD), and neuromuscular diseases.
Yesterday, ResMed closed at $36.79 per share, a price point significantly below the optimistic targets set by several leading brokers. Ord Minnett, for example, maintains a ‘buy’ rating on ResMed shares with a price target of $43.70.
Further bolstering a positive outlook, Morgans has also issued a ‘buy’ recommendation, coupled with a price target of $47.73. This assessment is largely influenced by ResMed’s second-quarter FY2026 results, which demonstrably surpassed market expectations across the board. The company reported:
- Double-Digit Growth: ResMed achieved robust double-digit growth in both revenue and earnings.
- Margin Expansion: Gross margins saw an expansion, indicating improved profitability.
- Strong Cash Flow: The company generated substantial cash flow, underscoring its financial health.
Morgans has subsequently revised its earnings forecasts and valuation upwards for ResMed, driven by enhanced operating leverage. From yesterday’s closing price, the updated target from Morgans suggests an impressive upside potential of nearly 30%.
Investment Considerations
The recent price corrections in both Computershare and ResMed, despite their underlying strong fundamentals and positive analyst ratings, present a potential opportunity for investors. While past performance is not indicative of future results, the current valuations, viewed against expert price targets, suggest that these ASX 200 companies may be trading at a discount.
For those considering an investment in Computershare Limited, it’s prudent to conduct thorough due diligence. Experts often recommend considering a diversified portfolio and seeking advice tailored to individual financial goals.
Similarly, ResMed’s recent performance, while showing a dip, is underpinned by strong financial results and optimistic future projections from market analysts. Investors interested in the healthcare technology sector may find ResMed’s current share price an attractive entry point.
As always, it is crucial for investors to perform their own research, consider their risk tolerance, and consult with a qualified financial advisor before making any investment decisions. The current market conditions, with broad index gains contrasted by individual stock pullbacks, highlight the importance of selective investing and understanding the specific drivers behind each company’s performance.
